表紙
市場調查報告書

皮膚T細胞性淋巴瘤(CTCL)- 市場洞見、流行病學、市場預測 2028年

Cutaneous T-Cell Lymphoma (CTCL) - Market Insights, Epidemiology and Market Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 524417
出版日期 內容資訊 英文 189 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
皮膚T細胞性淋巴瘤(CTCL)- 市場洞見、流行病學、市場預測 2028年 Cutaneous T-Cell Lymphoma (CTCL) - Market Insights, Epidemiology and Market Forecast - 2028
出版日期: 2019年12月01日內容資訊: 英文 189 Pages
簡介

皮膚T細胞性淋巴瘤(CTCL)是一種淋巴增生症候群,特徵是惡性T淋巴球往皮膚增生。CTCL被分類為非霍奇金氏淋巴瘤(NHL),也是統稱。皮膚T細胞性淋巴瘤(CTCL)是皮膚淋巴癌最常見的類型。被診斷為罹患皮膚淋巴癌的4人中有3人以上是CTCL,這種疾病有時會發生像是濕疹一樣的皮膚紅疹,對身體產生大範圍影響。 CTCL有各式各樣的亞型,其中最常見的類型是蕈狀肉芽腫。根據情況不同,CTCL,也就是皮膚T細胞性淋巴瘤,有可能不僅發病在皮膚,還有可能引起伴隨著感染、搔癢的腫瘤形成、剝離和潰瘍。在病程發展階段中,CTCL,也就是皮膚T細胞性淋巴瘤,會蔓延至淋巴結、內臟及末梢血管。 CTCL,也就是皮膚T細胞性淋巴瘤,並不是會危及生命的疾病,幾乎所有情況都能夠治療,但是無法完全治癒。

主要7國(美國、英國、德國、法國、義大利、西班牙、日本)在2018年罹患皮膚T細胞性淋巴瘤(CTCL)的人數是8,617人,該年的市場規模推估是7億8,524萬美元。

本報告調查了主要7國(美國、英國、德國、法國、義大利、西班牙、日本)的皮膚T細胞性淋巴瘤(CTCL)市場,並統整了疾病概要與現行治療法、已上市治療藥物及新藥檔案,主要7國的市場動向、流行病學預測、市場規模、部門別罹患人數變化及預測、unmet needs、市場成長因素及障礙等。

目錄

第1章 重要研究

第2章 皮膚T細胞性淋巴瘤(CTCL)市場概要

  • 皮膚T細胞性淋巴瘤(CTCL)的分佈(實際數值)
  • 皮膚T細胞性淋巴瘤(CTCL)的分佈(預測數值)

第3章 疾病背景與概要:皮膚T細胞性淋巴瘤(CTCL)

  • 簡介
  • 類型
  • 病期
  • 原因
  • 病狀生理
  • 症狀
  • 診斷

第4章 流行病學與患者人口

  • 主要研究結果
  • 人口與預測參數

第5章 主要7國的皮膚T細胞性淋巴瘤(CTCL)罹患人口

第6章 皮膚T細胞性淋巴瘤(CTCL)的流行病學:國別

  • 美國
    • 皮膚T細胞性淋巴瘤(CTCL)總罹病數
    • 皮膚T細胞性淋巴瘤(CTCL)罹病數:2次類型別
    • 皮膚T細胞性淋巴瘤(CTCL)罹病數:性別
    • 皮膚T細胞性淋巴瘤(CTCL)罹病數:病期別
  • EU5國
    • 德國
      • 皮膚T細胞性淋巴瘤(CTCL)總罹病數
      • 皮膚T細胞性淋巴瘤(CTCL)罹病數:2次類型別
      • 皮膚T細胞性淋巴瘤(CTCL)罹病數:性別
      • 皮膚T細胞性淋巴瘤(CTCL)罹病數:病期別
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本
    • 皮膚T細胞性淋巴瘤(CTCL)總罹病數
    • 皮膚T細胞性淋巴瘤(CTCL)罹病數:2次類型別
    • 皮膚T細胞性淋巴瘤(CTCL)罹病數:性別
    • 皮膚T細胞性淋巴瘤(CTCL)罹病數:病期別

第7章 治療演算法、現行治療

第8章 unmet needs

第9章 已上市治療藥

  • Istodax(Romidepsin):Celgene Corporation
    • 產品概述
    • 作用機制
    • 法規里程碑
    • 優缺點
    • 安全性及有效性
    • 產品檔案
  • Potelegio (Mogamulizumab):協和發酵麒麟
  • Valchlor/ Ledaga (Mechlorethamine):Actelion
  • Uvadex(Methoxsalen):Mallinckrodt Pharmaceuticals
  • Targretin (Bexarotene):衛采
  • Zolinza (Vorinostat):Merck Sharp & Dohme Corp.
  • Adcetris (Brentuximab Vedotin):Seattle Genetics

第10章 新藥

  • 第III相醫藥品分析 - 單株抗體與光線力學療法
  • 第II相醫藥品分析 - 組織蛋白去乙醯酶(HDAC)抑制劑
    • 產品概述
    • 法規里程碑
    • 臨床開發
    • 產品檔案
  • Resminostat:4SC AG
  • Remetinostat:Medivir AB

第11章 主要7國的皮膚T細胞性淋巴瘤(CTCL)市場分析

  • 主要研究結果
  • 主要7國的總市場規模
  • 主要7國的市場規模:早期
  • 主要7國的市場規模:晚期

第12章 美國市場預測

  • 美國的市場規模
    • 總市場規模
    • 早期皮膚T細胞性淋巴瘤(CTCL)市場:第一選擇藥別
    • 早期皮膚T細胞性淋巴瘤(CTCL)市場:第二選擇藥別
    • 晚期皮膚T細胞性淋巴瘤(CTCL)市場:第一選擇藥別
    • 晚期皮膚T細胞性淋巴瘤(CTCL)市場:第二選擇藥別

第13章 EU5國與日本市場的預測

  • 德國
    • 總市場規模
    • 早期皮膚T細胞性淋巴瘤(CTCL)市場:第一選擇藥別
    • 早期皮膚T細胞性淋巴瘤(CTCL)市場:第二選擇藥別
    • 晚期皮膚T細胞性淋巴瘤(CTCL)市場:第一選擇藥別
    • 晚期皮膚T細胞性淋巴瘤(CTCL)市場:第二選擇藥別
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第14章 市場的成長因素

第15章 市場障礙

第16章 附錄

第17章 調查方法

第18章 DelveInsight的服務內容

第19章 免責事項

第20章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0091

DelveInsight's 'Cutaneous T- Cell Lymphoma (CTCL) - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Cutaneous T- Cell Lymphoma (CTCL) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Cutaneous T- Cell Lymphoma (CTCL) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2028

Cutaneous T- Cell Lymphoma (CTCL) - Disease Understanding and Treatment Algorithm

Cutaneous T-cell lymphoma (CTCL) is a group of lympho proliferative disorders characterized by localization of neoplastic T lymphocytes to the skin. Collectively, CTCL is classified as a type of non-Hodgkin lymphoma (NHL). Cutaneous T-cell lymphomas (CTCL) are the most common types of skin lymphoma. More than 3 out of every 4 skin lymphomas diagnosed are CTCLs. They often appear as eczema-like skin rashes and can affect widespread parts of the body. There are different subtypes of CTCL. The most common type is mycosis fungoides. In some cases CTCL or Cutaneous T-Cell Lymphoma can affect more than just the skin and cause formation of tumor, exfoliation, and ulceration accompanied by infections and itching. In the advanced stages CTCL or Cutaneous T-Cell Lymphoma begins to extend to lymph nodes, internal organs and peripheral blood. CTCL or Cutaneous T-Cell Lymphoma is not a life threatening disease and mostly it can be treated but not cured.

The DelveInsight Cutaneous T- Cell Lymphoma (CTCL) market report gives a thorough understanding of the Cutaneous T- Cell Lymphoma (CTCL) by including details such as disease definition, types, staging, causes, pathophysiology, symptoms and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Cutaneous T- Cell Lymphoma (CTCL) in the United States, EU5 (Germany, Spain, France, Italy, the UK) & Japan.

Cutaneous T- Cell Lymphoma (CTCL) Epidemiology

The Cutaneous T- Cell Lymphoma (CTCL) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report is segmented by incident population, sub-type specific incident population, gender-specific incidence population and stage specific incidence cases of Cutaneous T- Cell Lymphoma (CTCL).

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the incident population of Cutaneous T- Cell Lymphoma (CTCL) was estimated to be 8,617 [7MM] in 2018. United States accounts for the highest Cutaneous T- Cell Lymphoma (CTCL) cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Among the EU5 countries UK had the highest prevalent patient population of Cutaneous T- Cell Lymphoma (CTCL), followed by Germany.

Cutaneous T- Cell Lymphoma (CTCL) Drug Chapters

This segment of the Cutaneous T- Cell Lymphoma (CTCL) report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

There are currently seven approved therapies including Istodax, Potelegio and Uvadex, which are being used for the treatment of Cutaneous T- Cell Lymphoma (CTCL). However these drugs have shown to be effective in managing the Cutaneous T- Cell Lymphoma (CTCL) by reducing symptoms, risk of complications, and exacerbations among persons with CTCL. Though there are treatments available for Cutaneous T Cell Lymphoma (CTCL) but the available options are limited. There is no cure available for CTCL and the available treatments are for management of CTCL. The patients are treated with consecutive therapies until loss of response or without treatment 'expectant therapy' if no suitable therapy is available. Detailed chapters for all of these marketed drugs along with the other promising candidates like Adcetris and Zolinza have also been covered in the report.

Cutaneous T- Cell Lymphoma (CTCL) Market Outlook

The Cutaneous T- Cell Lymphoma (CTCL) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the global market of Cutaneous T- Cell Lymphoma (CTCL) was estimated to be USD 785.24 million in 2018. The United States accounts for the largest market size of Cutaneous T- Cell Lymphoma (CTCL), in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan.

The dynamics of Cutaneous T- Cell Lymphoma (CTCL) market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period 2019-2028. Launch of potential therapies may increase market size in the coming years, assisted by an increase in diagnosed prevalent population of Cutaneous T- Cell Lymphoma (CTCL). Upcoming therapies such as Soligenix's SGX301, Janssen's Quisinostat and many more, have the potential to create a significant positive shift in the Cutaneous T- Cell Lymphoma (CTCL) market size. The United States accounts for the largest market size of Cutaneous T- Cell Lymphoma (CTCL), in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan.

Cutaneous T- Cell Lymphoma (CTCL) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The market size of Cutaneous T- Cell Lymphoma (CTCL) includes the drug-uptake for individual therapies, which is further segmented on the basis of market size and market share by Line of therapy and Route of Administration.

To counter current unmet needs of the market and to provide better treatment options for Cutaneous T- Cell Lymphoma (CTCL), several companies are working robustly on developing new therapies with novel mechanism of action.

Cutaneous T- Cell Lymphoma (CTCL) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Cutaneous T- Cell Lymphoma (CTCL) Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Cutaneous T- Cell Lymphoma (CTCL) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Cutaneous T- Cell Lymphoma (CTCL) market.
  • Organize sales and marketing efforts by identifying the best opportunities for Cutaneous T- Cell Lymphoma (CTCL) market.
  • To understand the future market competition in the Cutaneous T- Cell Lymphoma (CTCL) market.

Table of Contents

1 Key Insights

2 Cutaneous T- Cell Lymphoma (CTCL): Market Overview at a Glance

  • 2.1 Total Market Share (%) Distribution of Cutaneous T- Cell Lymphoma (CTCL) in 2016
  • 2.2 Total Market Share (%) Distribution of Cutaneous T- Cell Lymphoma (CTCL) in 2027

3 Disease Background and Overview: Cutaneous T- Cell Lymphoma (CTCL)

  • 3.1 Introduction
  • 3.2 Types
  • 3.3 Staging
  • 3.4 Causes
  • 3.5 Pathophysiology
  • 3.6 Symptoms
  • 3.7 Diagnosis

4 Epidemiology and Patient Population

  • 4.1 Key Findings
  • 4.2 Population and Forecast Parameters

5 Incident Population of Cutaneous T- Cell Lymphoma (CTCL) in 7MM

6 Country Wise-Epidemiology of Cutaneous T- Cell Lymphoma (CTCL)

  • 6.1 United States
    • 6.1.1 Incident Population of CTCL in the United States
    • 6.1.2 Sub Type Specific Incident Population of CTCL in the United States
    • 6.1.3 Gender Specific Incidence of CTCL in the United States
    • 6.1.4 Stage-Specific Incidence of CTCL (MF/SS) in the United States
  • 6.2 EU5 Countries
  • 6.3 Germany
    • 6.3.1 Incident Population of CTCL in Germany
    • 6.3.2 Sub Type Specific Incident Population of CTCL in Germany
    • 6.3.3 Gender Specific Incidence of CTCL in Germany
    • 6.3.4 Stage-Specific Incidence of CTCL (MF/SS) in Germany
  • 6.4 France
    • 6.4.1 Incident Population of CTCL in France
    • 6.4.2 Sub Type Specific Incident Population of CTCL in France
    • 6.4.3 Gender Specific Incidence of CTCL in France
    • 6.4.4 Stage-Specific Incidence of CTCL (MF/SS) in France
  • 6.5 Italy
    • 6.5.1 Incident Population of CTCL in Italy
    • 6.5.2 Sub Type Specific Incident Population of CTCL in Italy
    • 6.5.3 Gender Specific Incidence of CTCL in Italy
    • 6.5.4 Stage-Specific Incidence of CTCL (MF/SS) in Italy
  • 6.6 Spain
    • 6.6.1 Incident Population of CTCL in Spain
    • 6.6.2 Sub Type Specific Incident Population of CTCL in Spain
    • 6.6.3 Gender Specific Incidence of CTCL in Spain
    • 6.6.4 Stage-Specific Incidence of CTCL (MF/SS) in Spain
  • 6.7 The United Kingdom
    • 6.7.1 Incident Population of CTCL in the United Kingdom
    • 6.7.2 Sub Type Specific Incident Population of CTCL in the United Kingdom
    • 6.7.3 Gender Specific Incidence of CTCL in the United Kingdom
    • 6.7.4 Stage-Specific Incidence of CTCL (MF/SS) in the United Kingdom
  • 6.8 Japan
    • 6.8.1 Incident Population of CTCL in Japan
    • 6.8.2 Sub Type Specific Incident Population of CTCL in Japan
    • 6.8.3 Gender Specific Incidence of CTCL in Japan
    • 6.8.4 Stage-Specific Incidence of CTCL (MF/SS) in Japan

7 Treatment Algorithm, Current Treatment, and Medical Practices

  • 7.1 International Lymphoma Radiation Oncology Group Guidelines for Modern Radiation Therapy for Primary Cutaneous Lymphomas
  • 7.2 United States
    • 7.2.1 NCCN Guidelines
  • 7.3 Europe
    • 7.3.1 ESMO Guidelines
    • 7.3.2 Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group Guidelines
    • 7.3.3 EORTC recommendations for the treatment of mycosis fungoides/Se´zary syndrome

8 Unmet Needs

9 Marketed Drugs

  • 9.1 Istodax (Romidepsin): Celgene Corporation
    • 9.1.1 Drug Description
    • 9.1.2 Mechanism of Action:
    • 9.1.3 Regulatory Milestones
    • 9.1.4 Advantages and Disadvantages
    • 9.1.5 Safety and Efficacy
    • 9.1.6 Advantages & Disadvantages
    • 9.1.7 Product Profile
  • 9.2 Potelegio (Mogamulizumab): Kyowa Hakko Kirin Co, Ltd.
    • 9.2.1 Drug Description
    • 9.2.2 Mechanism of Action
    • 9.2.3 Regulatory Milestones
    • 9.2.4 Advantages & Disadvantages
    • 9.2.5 Safety and Efficacy
    • 9.2.6 Product Profile
  • 9.3 Valchlor/ Ledaga (Mechlorethamine): Actelion
    • 9.3.1 Drug Description
    • 9.3.2 Mechanism of Action
    • 9.3.3 Regulatory Milestones
    • 9.3.4 Advantages & Disadvantages
    • 9.3.5 Safety and Efficacy
    • 9.3.6 Product Profile
  • 9.4 Uvadex (Methoxsalen): Mallinckrodt Pharmaceuticals
    • 9.4.1 Drug Description
    • 9.4.2 Mechanism of Action
    • 9.4.3 Regulatory Milestones
    • 9.4.4 Advantages & Disadvantages
    • 9.4.5 Safety and Efficacy
    • 9.4.6 Product Profile
  • 9.5 Targretin (Bexarotene): Eisai Co., Ltd.
    • 9.5.1 Drug Description
    • 9.5.2 Mechanism of Action
    • 9.5.3 Regulatory Milestones
    • 9.5.4 Advantages & Disadvantages
    • 9.5.5 Safety and Efficacy of Targretin
    • 9.5.6 Product Profile
  • 9.6 Zolinza (Vorinostat): Merck Sharp & Dohme Corp.
    • 9.6.1 Drug Description
    • 9.6.2 Mechanism of Action
    • 9.6.3 Advantages & Disadvantages
    • 9.6.4 Safety and Efficacy of Zolinza
    • 9.6.5 Product Profile
  • 9.7 Adcetris (Brentuximab Vedotin): Seattle Genetics
    • 9.7.1 Drug Description
    • 9.7.2 Mechanism of Action
    • 9.7.3 Regulatory Milestones
    • 9.7.4 Advantages & Disadvantages
    • 9.7.5 Safety and Efficacy of Adcetris
    • 9.7.6 Product Profile

10 Emerging Therapies

  • 10.1 Phase-III Drugs Analysis - Monoclonal Antibodies and Photodynamic Therapy
  • 10.2 Phase-II Drugs Analysis - Histone Deacetylase (HDAC) Inhibitors
  • 10.3 SGX301: Soligenix
    • 10.3.1 Product Description
    • 10.3.2 Regulatory Milestones
    • 10.3.3 Clinical Development
    • 10.3.4 Product Profile
  • 10.4 Quisinostat: Janssen
    • 10.4.1 Product Description
    • 10.4.2 Regulatory Milestones
    • 10.4.3 Clinical Development
    • 10.4.4 Safety and Efficacy
    • 10.4.5 Product Profile
  • 10.5 Resminostat: 4SC AG
    • 10.5.1 Product Description
    • 10.5.2 Regulatory Milestones
    • 10.5.3 Clinical Development
    • 10.5.4 Product Profile
  • 10.6 Remetinostat: Medivir AB
    • 10.6.1 Product Description
    • 10.6.2 Regulatory Milestones
    • 10.6.3 Clinical Development
    • 10.6.4 Safety and Efficacy
    • 10.6.5 Product Profile

11 Cutaneous T- Cell Lymphoma (CTCL): 7 Major Market Analysis

  • 11.1 Key Findings
  • 11.2 Total Market Size of Cutaneous T- Cell Lymphoma (CTCL) in 7MM
  • 11.3 Early Stage Market Size of Cutaneous T- Cell Lymphoma (CTCL) in 7 MM
  • 11.4 Late Stage Market Size of Cutaneous T- Cell Lymphoma (CTCL) in 7 MM

12 The United States Market Outlook

  • 12.1 United States Market Size
    • 12.1.1 Total Market size of Cutaneous T- Cell Lymphoma (CTCL) in US
    • 12.1.2 Early Stage Market Size of CTCL by First Line of Therapies in US
    • 12.1.3 Early Stage Market Size of CTCL by Second Line of Therapies in US
    • 12.1.4 Late Stage Market Size of CTCL by First Line of Therapies in US
    • 12.1.5 Late Stage Market Size of CTCL by Second Line of Therapies in US

13 EU-5 Countries: Market Outlook

  • 13.1 Germany
    • 13.1.1 Total Market size of Cutaneous T- Cell Lymphoma (CTCL) in Germany
    • 13.1.2 Early Stage Market Size of CTCL by First Line of Therapies in Germany
    • 13.1.3 Early Stage Market Size of CTCL by Second Line of Therapies in Germany
    • 13.1.4 Late Stage Market Size of CTCL by First Line of Therapies in Germany
    • 13.1.5 Late Stage Market Size of CTCL by Second Line of Therapies in Germany
  • 13.2 France
    • 13.2.1 Total Market size of Cutaneous T- Cell Lymphoma (CTCL) in France
    • 13.2.2 Early Stage Market Size of CTCL by First Line of Therapies in France
    • 13.2.3 Early Stage Market Size of CTCL by Second Line of Therapies in France
    • 13.2.4 Late Stage Market Size of CTCL by First Line of Therapies in France
    • 13.2.5 Late Stage Market Size of CTCL by Second Line of Therapies in France

13.2.6

  • 13.3 Italy
    • 13.3.1 Total Market size of Cutaneous T- Cell Lymphoma (CTCL) in Italy
    • 13.3.2 Early Stage Market Size of CTCL by First Line of Therapies in Italy
    • 13.3.3 Early Stage Market Size of CTCL by Second Line of Therapies in Italy
    • 13.3.4 Late Stage Market Size of CTCL by First Line of Therapies in Italy
    • 13.3.5 Late Stage Market Size of CTCL by Second Line of Therapies in Italy
  • 13.4 Spain
    • 13.4.1 Total Market size of Cutaneous T- Cell Lymphoma (CTCL) in Spain
    • 13.4.2 Early Stage Market Size of CTCL by First Line of Therapies in Spain
    • 13.4.3 Early Stage Market Size of CTCL by Second Line of Therapies in Spain
    • 13.4.4 Late Stage Market Size of CTCL by First Line of Therapies in Spain
    • 13.4.5 Late Stage Market Size of CTCL by Second Line of Therapies in Spain
  • 13.5 United Kingdom
    • 13.5.1 Total Market size of Cutaneous T- Cell Lymphoma (CTCL) in UK
    • 13.5.2 Early Stage Market Size of CTCL by First Line of Therapies in UK
    • 13.5.3 Early Stage Market Size of CTCL by Second Line of Therapies in UK
    • 13.5.4 Late Stage Market Size of CTCL by First Line of Therapies in UK
    • 13.5.5 Late Stage Market Size of CTCL by Second Line of Therapies in UK
  • 13.6 Japan: Market Outlook
    • 13.6.1 Total Market size of Cutaneous T- Cell Lymphoma (CTCL) in Japan
    • 13.6.2 Early Stage Market Size of CTCL by First Line of Therapies in Japan
    • 13.6.3 Early Stage Market Size of CTCL by Second Line of Therapies in Japan
    • 13.6.4 Late Stage Market Size of CTCL by First Line of Therapies in Japan
    • 13.6.5 Late Stage Market Size of CTCL by Second Line of Therapies in Japan

14 Market Drivers

15 Market Barriers

16 Appendix

17 Report Methodology

  • 17.1 Sources Used

18 DelveInsight Capabilities

19 Disclaimer

20 About DelveInsight

List of Tables

TABLE 1: TOTAL INCIDENT POPULATION OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN THE 7MM (2016-2027)

TABLE 2: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN THE US (2016-2027)

TABLE 3: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE US (2016-2027)

TABLE 4: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE US (2016-2027)

TABLE 5: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE US (2016-2027)

TABLE 6: LATE STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE US (2016-2027)

TABLE 7: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN GERMANY (2016-2027)

TABLE 8: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN GERMANY (2016-2027)

TABLE 9: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN GERMANY (2016-2027)

TABLE 10: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN GERMANY (2016-2027)

TABLE 11: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN FRANCE (2016-2027)

TABLE 12: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN FRANCE (2016-2027)

TABLE 13: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN FRANCE (2016-2027)

TABLE 14: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN FRANCE (2016-2027)

TABLE 15: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN ITALY (2016-2027)

TABLE 16: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN ITALY (2016-2027)

TABLE 17: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN ITALY (2016-2027)

TABLE 18: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN ITALY (2016-2027)

TABLE 19: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN SPAIN (2016-2027)

TABLE 20: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN SPAIN (2016-2027)

TABLE 21: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN SPAIN (2016-2027)

TABLE 22: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN SPAIN (2016-2027)

TABLE 23: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN THE UK (2016-2027)

TABLE 24: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN SPAIN (2016-2027)

TABLE 25: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE UK (2016-2027)

TABLE 26: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE UK (2016-2027)

TABLE 27: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN JAPAN (2016-2027)

TABLE 28: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN SPAIN (2016-2027)

TABLE 29: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN JAPAN (2016-2027)

TABLE 30: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN JAPAN (2016-2027)

TABLE 31 : RECOMMENDATIONS FOR TREATMENT OF CTCL BY RADIATION THERAPY

TABLE 32: BAD GUIDELINES FOR MYCOSIS FUNGOIDES AND SEZARY SYNDROME

TABLE 33 : RECOMMENDATIONS FOR TREATMENT OF MF STAGES IA, IB, AND IIA

TABLE 34: 7 MAJOR MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)

TABLE 35: 7 MAJOR MARKET SIZE OF EARLY STAGE CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)

TABLE 36: 7 MAJOR MARKET SIZE OF LATE STAGE CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)

TABLE 37: UNITED STATES MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)

TABLE 38: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN THE US, IN USD MILLION (2016-2027)

TABLE 39: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN THE US, IN USD MILLION (2016-2027)

TABLE 40: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN THE US, IN USD MILLION (2016-2027)

TABLE 41: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN THE US, IN USD MILLION (2016-2027)

TABLE 42: GERMANY MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)

TABLE 43: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN GERMANY, IN USD MILLION (2016-2027)

TABLE 44: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN GERMANY, IN USD MILLION (2016-2027)

TABLE 45: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN GERMANY, IN USD MILLION (2016-2027)

TABLE 46: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN GERMANY, IN USD MILLION (2016-2027)

TABLE 47: FRENCH MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)

TABLE 48: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN FRANCE, IN USD MILLION (2016-2027)

TABLE 49: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN FRANCE, IN USD MILLION (2016-2027)

TABLE 50: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN FRANCE, IN USD MILLION (2016-2027)

TABLE 51: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN FRANCE, IN USD MILLION (2016-2027)

TABLE 52: ITALIAN MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)

TABLE 53: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN ITALY, IN USD MILLION (2016-2027)

TABLE 54: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN ITALY, IN USD MILLION (2016-2027)

TABLE 55: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN ITALY, IN USD MILLION (2016-2027)

TABLE 56: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN ITALY, IN USD MILLION (2016-2027)

TABLE 57: SPANISH MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)

TABLE 58: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN SPAIN, IN USD MILLION (2016-2027)

TABLE 59: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN SPAIN, IN USD MILLION (2016-2027)

TABLE 60: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN SPAIN, IN USD MILLION (2016-2027)

TABLE 61: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN SPAIN, IN USD MILLION (2016-2027)

TABLE 62: UK MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)

TABLE 63: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN UK, IN USD MILLION (2016-2027)

TABLE 64: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN UK, IN USD MILLION (2016-2027)

TABLE 65: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN UK, IN USD MILLION (2016-2027)

TABLE 66: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN UK, IN USD MILLION (2016-2027)

TABLE 67: JAPANESE MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)

TABLE 68: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN JAPAN, IN USD MILLION (2016-2027)

TABLE 69: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN JAPAN, IN USD MILLION (2016-2027)

TABLE 70: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN JAPAN, IN USD MILLION (2016-2027)

TABLE 71: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN JAPAN, IN USD MILLION (2016-2027)

List of Figures

FIGURE 1: STAGING OF CUTANEOUS T-CELL LYMPHOMA: TNMB CLASSIFICATION

FIGURE 2: TOTAL INCIDENT PATIENT POPULATION OF CTCL IN THE 7MM (2016-2027)

FIGURE 3: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN THE US (2016-2027)

FIGURE 4: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE US (2016-2027)

FIGURE 5: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE US (2016-2027)

FIGURE 6: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE US (2016-2027)

FIGURE 7: LATE STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE US (2016-2027)

FIGURE 8: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN GERMANY (2016-2027)

FIGURE 9: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN GERMANY (2016-2027)

FIGURE 10: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN GERMANY (2016-2027)

FIGURE 11: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN GERMANY (2016-2027)

FIGURE 12: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN FRANCE (2016-2027)

FIGURE 13: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN FRANCE (2016-2027)

FIGURE 14: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN FRANCE (2016-2027)

FIGURE 15: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN FRANCE (2016-2027)

FIGURE 16: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN ITALY (2016-2027)

FIGURE 17: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN ITALY (2016-2027)

FIGURE 18: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN ITALY (2016-2027)

FIGURE 19: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN ITALY (2016-2027)

FIGURE 20: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN SPAIN (2016-2027)

FIGURE 21: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN SPAIN (2016-2027)

FIGURE 22: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN SPAIN (2016-2027)

FIGURE 23: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN SPAIN (2016-2027)

FIGURE 24: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN THE UK (2016-2027)

FIGURE 25: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE UK (2016-2027)

FIGURE 26: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE UK (2016-2027)

FIGURE 27: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN THE UK (2016-2027)

FIGURE 28: INCIDENT POPULATION OF CUTANEOUS T-CELL LYMPHOMA IN JAPAN (2016-2027)

FIGURE 29: SUB-TYPE SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN JAPAN (2016-2027)

FIGURE 30: GENDER SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN JAPAN (2016-2027)

FIGURE 31: STAGE-SPECIFIC INCIDENCE OF CUTANEOUS T-CELL LYMPHOMA IN JAPAN (2016-2027)

FIGURE 32: TREATMENT ALGORITHM OF CUTANEOUS T- CELL LYMPHOMA

FIGURE 33: TREATMENT ALGORITHM OF CUTANEOUS T- CELL LYMPHOMA

FIGURE 34:TREATMENT FOR STAGE IA OF CUTANEOUS T- CELL LYMPHOMA

FIGURE 35:TREATMENT FOR STAGE IB-IIA OF CUTANEOUS T- CELL LYMPHOMA

FIGURE 36:TREATMENT FOR STAGE IIB OF CUTANEOUS T- CELL LYMPHOMA

FIGURE 37:TREATMENT FOR STAGE III OF CUTANEOUS T- CELL LYMPHOMA

FIGURE 38:TREATMENT FOR STAGE IV OF CUTANEOUS T- CELL LYMPHOMA

FIGURE 39:TREATMENT FOR PRIMARY CUTANEOUS CD30+ T-CELL LYMPHOPROLIFERATIVE DISORDERS

FIGURE 40:TREATMENT FOR LYMPHOMATOID PAPULOSIS

FIGURE 41: UNMET NEEDS OF CUTANEOUS T- CELL LYMPHOMA (CTCL)

FIGURE 42: 7 MAJOR MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)

FIGURE 43: 7MM SIZE OF EARLY STAGE CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)

FIGURE 44: 7MM SIZE OF LATE STAGE CUTANEOUS T- CELL LYMPHOMA (CTCL) IN USD MILLION (2016-2027)

FIGURE 45: MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN THE UNITED STATES, USD MILLIONS (2016-2027)

FIGURE 46: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN THE US, IN USD MILLION (2016-2027)

FIGURE 47: EARLY STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN THE US, IN USD MILLION (2016-2027)

FIGURE 48: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN THE US, IN USD MILLION (2016-2027)

FIGURE 49: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN THE US, IN USD MILLION (2016-2027)

FIGURE 50: MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN GERMANY, USD MILLIONS (2016-2027)

FIGURE 51: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN GERMANY, IN USD MILLION (2016-2027)

FIGURE 52: EARLY STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN GERMANY, IN USD MILLION (2016-2027)

FIGURE 53: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN GERMANY, IN USD MILLION (2016-2027)

FIGURE 54: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN GERMANY, IN USD MILLION (2016-2027)

FIGURE 55: MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN FRANCE, USD MILLIONS (2016-2027)

FIGURE 56: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN FRANCE, IN USD MILLION (2016-2027)

FIGURE 57: EARLY STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN FRANCE, IN USD MILLION (2016-2027)

FIGURE 58: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN FRANCE, IN USD MILLION (2016-2027)

FIGURE 59: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN FRANCE, IN USD MILLION (2016-2027)

FIGURE 60: MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN ITALY, USD MILLIONS (2016-2027)

FIGURE 61: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN ITALY, IN USD MILLION (2016-2027)

FIGURE 62: EARLY STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN ITALY, IN USD MILLION (2016-2027)

FIGURE 63: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN ITALY, IN USD MILLION (2016-2027)

FIGURE 64: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN ITALY, IN USD MILLION (2016-2027)

FIGURE 65: MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN SPAIN, USD MILLIONS (2016-2027)

FIGURE 66: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN SPAIN, IN USD MILLION (2016-2027)

FIGURE 67: EARLY STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN SPAIN, IN USD MILLION (2016-2027)

FIGURE 68: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN SPAIN, IN USD MILLION (2016-2027)

FIGURE 69: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN SPAIN, IN USD MILLION (2016-2027)

FIGURE 70: MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN UK, USD MILLIONS (2016-2027)

FIGURE 71: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN UK, IN USD MILLION (2016-2027)

FIGURE 72: EARLY STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN UK, IN USD MILLION (2016-2027)

FIGURE 73: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN UK, IN USD MILLION (2016-2027)

FIGURE 74: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN UK, IN USD MILLION (2016-2027)

FIGURE 75: MARKET SIZE OF CUTANEOUS T- CELL LYMPHOMA (CTCL) IN JAPAN, USD MILLIONS (2016-2027)

FIGURE 76: EARLY STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN JAPAN, IN USD MILLION (2016-2027)

FIGURE 77: EARLY STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN JAPAN, IN USD MILLION (2016-2027)

FIGURE 78: LATE STAGE MARKET SIZE OF CTCL BY FIRST LINE OF THERAPIES IN JAPAN, IN USD MILLION (2016-2027)

FIGURE 79: LATE STAGE MARKET SIZE OF CTCL BY SECOND LINE OF THERAPIES IN JAPAN, IN USD MILLION (2016-2027)

FIGURE 80: MARKET DRIVERS

FIGURE 81: MARKET BARRIERS

Back to Top